Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the Safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty

Samuel Golpanian, Darcy L. DiFede, Marietsy V. Pujol, Maureen H. Lowery, Silvina Levis-Dusseau, Bradley J. Goldstein, Ivonne H. Schulman, Bangon Longsomboon, Ariel Wolf, Aisha Khan, Alan W. Heldman, Pascal Goldschmidt-Clermont, Joshua M. Hare

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the Safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty'. Together they form a unique fingerprint.

Medicine & Life Sciences